Stifel analysts adjusted their outlook on Inspire Medical Systems (NYSE:INSP), reducing the price target to $190 from the previous $200 while maintaining a Hold rating on the stock. The revision ...

The global sleep apnea implants market is expected to grow from USD 317.1 million in 2023 to USD 1,158.1 million by 2033, at ...

Wells Fargo analyst Larry Biegelsen maintained a Hold rating on Inspire Medical Systems (INSP – Research Report) yesterday and set a price ...

Awareness of sleep apnea and its relatively common and effective treatment has grown over the past three decades.

including snoring and sleep apnea. This is likely true for a few reasons. Learn about the role of your neck size in the anatomy associated with sleep-disordered breathing disorders like obstructive ...

Obstructive sleep apnea may have some surprising signs and symptoms of the condition. You may expect it in someone who is overweight, snores loudly, and repeatedly wakes up gasping out of sleep.

Her work has appeared in Women's Health, SELF, Prevention, The Washington Post, and more. Sleep apnea impacts about 30 million American adults, making it a common sleep disorder. But while plenty ...

On the other hand, intermittent upper airway obstructions in OSAS during sleep would cause hypoxia with subsequent decrease in PaO 2 and increase in PaCO 2. The episodic vascular insufficiency may ...

The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but potentially serious sleep-related breathing disorder, making it the ...

The U.S. Food and Drug Administration (FDA) has granted approval for Zepbound, a weight-loss medication, to treat moderate to severe obstructive sleep apnea (OSA) in individuals with obesity.

Inspire is a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea. Inspire’s proprietary ...